Expression of prostate-specific membrane antigen in renal cortical tumors

Modern Pathology

Volumn 21, Issue 6, 2008, Pages 727-732

  Al Ahmadie, Hikmat A ^a   Olgac, Semra ^b   Gregor, Polly D ^b   Tickoo, Satish K ^b   Fine, Samson W ^b   Kondagunta, G Varuni ^b   Scher, Howard I ^b   Morris, Michael J ^b   Russo, Paul ^b   Motzer, Robert J ^b   Reuter, Victor E ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Immunohistochemistry; Oncocytoma; PSMA; Renal cell carcinoma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; KIDNEY CORTEX; KIDNEY EPITHELIUM; KIDNEY TUMOR; MAJOR CLINICAL STUDY; NEPHRECTOMY; ONCOCYTOMA; PRIORITY JOURNAL;

ANTIGENS, SURFACE; CARCINOMA, RENAL CELL; ENDOTHELIAL CELLS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 44349182533     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.42     Document Type: Article

References (39)

1. Skinnider BF, Amin MB. An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol 2005;22:51-68.
2. Eble JN, Togashi K, Pisani P. Tumors of the Kidney. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds). Pathology and Genetics Tumours of the Urinary System and Male Genital Organs, Vol, IARC Press: Lyon, 2004, pp 9-87.
3. O'Keefe DS, Su SL, Bacich DJ, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1998;1443:113-127.
4. Israeli RS, Powell CT, Fair WR, et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-230.
5. Rinker-Schaeffer CW, Hawkins AL, Su SL, et al. Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics 1995;30:105-108.
6. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996;93:749-753.
7. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-1451.
8. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-935.
9. Troyer JK, Beckett ML, Wright Jr GL. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-558.
10. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-3198.
11. Grauer LS, Lawler KD, Marignac JL, et al. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res 1998;58:4787-4789.
12. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-3634.
13. Gregor PD, Wolchok JD, Turaga V, et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 2005;116:415-421.
14. Sokoloff RL, Norton KC, Gasior CL, et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 2000;43:150-157.
15. Lopes AD, Davis WL, Rosenstraus MJ, et al. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 1990;50:6423-6429.
16. Wright Jr GL, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-334.
17. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82:2256-2261.
18. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997;57:2321-2324.
19. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
20. Chang SS, Reuter VE, Heston WD, et al. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 2001;57:801-805.
21. Brassell SA, Rosner IL, McLeod DG. Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer. Curr Opin Urol 2005;15:163-166.
22. Wong TZ, Turkington TG, Polascik TJ, et al. Prosta-Scint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol 2005;184:676-680.
23. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003;170:S84-S88.
24. Helenon O, Correas JM, Balleyguier C, et al. Ultrasound of renal tumors. Eur Radiol 2001;11:1890-1901.
25. Kitamura H, Fujimoto H, Tobisu K, et al. Dynamic computed tomography and color Doppler ultrasound of renal parenchymal neoplasms: correlations with histopathological findings. Jpn J Clin Oncol 2004;34:78-81.
26. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003;170:2163-2172.
27. Jinzaki M, Ohkuma K, Tanimoto A, et al. Small solid renal lesions: usefulness of power Doppler US. Radiology 1998;209:543-550.
28. Hinkle GH, Burgers JK, Neal CE, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998;83:739-747.
29. Slovin SF. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets 2005;9:561-570.
30. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003;170:1717-1721.
31. Michaels EK, Blend M, Quintana JC. 111Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma. J Urol 1999;161:597-598.
32. Morris MJ, Divgi CR, Pandit-Taskar N, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res 2005;11:7454-7461.
33. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
34. Murphy GP, Greene TG, Tino WT, et al. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol 1998;160:2396-2401.
35. Zhang S, Zhang HS, Reuter VE, et al. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998;4:295-302.
36. Morris MJ, Pandit-Taskar N, Divgi CR, et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res 2007;13:2707-2713.
37. Gottlinger HG, Funke I, Johnson JP, et al. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986;38:47-53.
38. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/ neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671.
39. Chang SS, Heston WD. The clinical role of prostate-specific membrane antigen (PSMA). Urol Oncol 2002;7:7-12.